Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) insider Ian Fier sold 10,000 shares of Momenta Pharmaceuticals stock in a transaction on Friday, March 15th. The shares were sold at an average price of $13.92, for a total value of $139,200.00. Following the sale, the insider now directly owns 77,566 shares of the company’s stock, valued at approximately $1,079,718.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

MNTA stock traded up $0.05 during mid-day trading on Tuesday, hitting $14.58. 415,804 shares of the stock were exchanged, compared to its average volume of 642,645. Momenta Pharmaceuticals, Inc. has a 12 month low of $9.55 and a 12 month high of $32.20. The firm has a market cap of $1.39 billion, a P/E ratio of -7.18 and a beta of 2.24.

Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its quarterly earnings results on Friday, February 22nd. The biotechnology company reported ($0.07) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.46) by $0.39. Momenta Pharmaceuticals had a negative return on equity of 47.74% and a negative net margin of 232.92%. The firm had revenue of $42.80 million during the quarter, compared to analyst estimates of $17.11 million. During the same quarter in the previous year, the company posted $0.18 earnings per share. The company’s revenue was down 33.7% compared to the same quarter last year. On average, equities analysts expect that Momenta Pharmaceuticals, Inc. will post -1.71 earnings per share for the current fiscal year.

Several research firms recently issued reports on MNTA. BTIG Research began coverage on Momenta Pharmaceuticals in a research note on Monday. They set a “neutral” rating and a $14.15 price objective for the company. Zacks Investment Research lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, March 5th. BidaskClub raised Momenta Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Friday, January 18th. Stifel Nicolaus reaffirmed a “buy” rating and set a $29.00 price target on shares of Momenta Pharmaceuticals in a research note on Friday, February 22nd. Finally, ValuEngine lowered Momenta Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, January 2nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and two have issued a buy rating to the company’s stock. The company has an average rating of “Hold” and a consensus price target of $22.03.

Hedge funds have recently modified their holdings of the business. Louisiana State Employees Retirement System increased its holdings in shares of Momenta Pharmaceuticals by 4.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 36,004 shares of the biotechnology company’s stock worth $397,000 after buying an additional 1,504 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in shares of Momenta Pharmaceuticals by 41.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,880 shares of the biotechnology company’s stock worth $65,000 after buying an additional 1,723 shares during the period. American International Group Inc. increased its holdings in shares of Momenta Pharmaceuticals by 3.3% in the fourth quarter. American International Group Inc. now owns 62,451 shares of the biotechnology company’s stock worth $689,000 after buying an additional 2,003 shares during the period. Piedmont Investment Advisors Inc. increased its holdings in shares of Momenta Pharmaceuticals by 25.0% in the fourth quarter. Piedmont Investment Advisors Inc. now owns 22,522 shares of the biotechnology company’s stock worth $249,000 after buying an additional 4,511 shares during the period. Finally, State of Alaska Department of Revenue increased its holdings in shares of Momenta Pharmaceuticals by 25.6% in the fourth quarter. State of Alaska Department of Revenue now owns 32,101 shares of the biotechnology company’s stock worth $354,000 after buying an additional 6,547 shares during the period. 95.08% of the stock is owned by hedge funds and other institutional investors.

WARNING: “Momenta Pharmaceuticals, Inc. (MNTA) Insider Sells $139,200.00 in Stock” was originally published by Watch List News and is the property of of Watch List News. If you are viewing this report on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this report can be accessed at https://www.watchlistnews.com/momenta-pharmaceuticals-inc-mnta-insider-sells-139200-00-in-stock/2902557.html.

About Momenta Pharmaceuticals

Momenta Pharmaceuticals, Inc, a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy.

Featured Article: Why do companies issue convertible shares?

Insider Buying and Selling by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Receive News & Ratings for Momenta Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.